NCT06413095View on ClinicalTrials.gov

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 22, 2023

Study Completion Date

June 22, 2023

Conditions
Head and Neck Squamous Cell CarcinomaSoft Tissue Sarcoma
Interventions
BIOLOGICAL

Pembrolizumab

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

MK-0482 + Pembrolizumab

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

MK-4830 + Pembrolizumab

Intratumoral microdose injection by the CIVO device.

Trial Locations (11)

10467

Montefiore Medical Center, The Bronx

19107

University of Pennsylvania, Philadelphia

27599

University of North Carolina, Chapel Hill

29406

Sarah Cannon Medical Center, Charleston

30308

Emory Winship Cancer Institute, Atlanta

45219

UC Health, Cincinnati

71115

LSU Health Sciences Center - Shreveport, Shreveport

77401

UT Health Houston, Houston

95817

UC Davis, Sacramento

97239

Oregon Health & Science University (OHSU), Portland

98109

University of Washington, Seattle

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Presage Biosciences

INDUSTRY